Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) traded down 49.5% on Tuesday . The company traded as low as $2.02 and last traded at $2.02. 400 shares changed hands during mid-day trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Price Performance
The company has a 50-day moving average price of $2.02 and a 200-day moving average price of $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Articles
- Five stocks we like better than H-CYTE
- Using the MarketBeat Stock Split Calculator
- 3 Mid-Cap Medical Stocks Outperforming the Market
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- The Top-Ranked Insider Buys From April by Market Cap
- Consumer Staples Stocks, Explained
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
